Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Immuron Limited ( (AU:IMC) ) has provided an update.
Immuron Limited has called an extraordinary general meeting of shareholders for 12 February 2026 in Melbourne to seek approval for the ratification of two substantial prior share issuances. Shareholders will be asked to ratify the issue of 28,278,923 shares under ASX Listing Rule 7.1 and a further 26,821,997 shares under Listing Rule 7.1A, moves that effectively regularize past capital-raising activities and restore the company’s capacity to issue additional equity in the future. The resolutions, if approved, will support Immuron’s flexibility in accessing capital markets going forward, which is significant for its ongoing funding needs and could influence future dilution, governance considerations, and the company’s ability to finance its development and commercial objectives.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
More about Immuron Limited
Immuron Limited, listed on both the ASX and Nasdaq, operates in the biopharmaceutical sector, focusing on the development and commercialization of specialty immunotherapy products. The company targets global healthcare markets through its dual listing and relies on equity capital raisings as an important component of its funding strategy.
Average Trading Volume: 1,175,494
Technical Sentiment Signal: Sell
Current Market Cap: A$11.76M
See more data about IMC stock on TipRanks’ Stock Analysis page.